Abstract: The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (1) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected from alumina and aluminum alkoxides and in a non-protic solvent wherein at least one carbon atom ortho to the hydroxy group in the hydroxy aryl compound is unsubstituted. The present application also includes compounds of Formula (1).

Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.

Abstract: A trifunctional molecule comprising a target-specific ligand, a ligand that binds a protein associated with the TCR complex and a T cell receptor signaling domain polypeptide is provided. The ligand that binds a protein associated with a TCR complex is UCHT1 with a Y182T mutation. Engineering T cells with this novel receptor engenders antigen specific activation of numerous T cell functions, including cytokine production, degranulation and cytolysis.

Abstract: Methods of manufacturing conductive molybdenum disulfide (MoS2) are described herein. The methods include mixing a molybdenum disulfide powder in a liquid to form a molybdenum disulfide suspension, sonicating the molybdenum disulfide suspension for a first period of time at a first temperature, and retrieving the conductive molybdenum disulfide from the sonicated molybdenum disulfide suspension. Methods of manufacturing conductive forms of other transition metal dichalcogenides are also described. Materials produced by the methods described herein are also described.

Abstract: A method of detecting the expression level of miRNA markers in a biological sample obtained from a mammal is provided. The method incudes the steps of i) detecting the expression level of one or more miRNA markers selected from the group of miR-199a-3p, miR-143-3p, miR-340-5p, let-7b-5p, miR-21-5p, miR-17-5p, miR-20a-5p and miR-103a-3p, in the biological sample; ii) detecting the expression level of at least one miRNA reference marker selected from miR-148b-3p and miR-30e-5p in the biological sample; and iii) normalizing the expression level of the miRNA marker(s) against the expression level of the miRNA reference marker in the sample and in a control. The method is useful for the diagnosis of endometriosis, monitoring of patient response to treatment, and assessment of disease progression and/or severity.

Abstract: The present application relates to compounds of Formula I comprising an antibody binding domain (ABD) comprising a hapten that binds to an antibody in a subject, the antibody comprising a hapten binding site, an antibody labelling domain (ALD) comprising a functional group that forms a covalent bond with an amino acid in the antibody that is proximal to the hapten binding site and the formation of the covalent bond results in elimination of the ABD and either a target binding domain (TBD) or a detection moiety domain (DMD), each domain being optionally connected with independently selected linkers. The present application also includes methods and uses of the compounds, for example, for immune recognition of target cells by recruited labelled antibodies.

Abstract: The present invention relates to metformin for use in treating a patient, wherein the patient exhibits an increased level of GDF15 in response to metformin treatment; to methods of identifying a patient who will benefit or who will not benefit from metformin treatment; methods of treating a patient at risk of developing or suffering from a disease or disorder comprising administering therapeutically effective amount of metformin; methods of adapting the dosage of metformin; the usage of GDF15 as biomarker for identifying a patient who will benefit or who will not benefit from metformin treatment, kits for use in identifying a patient who will benefit from metformin treatment and the use of the kits, as well as methods of treating a patient or who will not benefit from metformin treatment.

Abstract: The present application is directed to methods of performing chemical reactions, including multi-step chemical reactions in which two or more of the reagents in the chemical reaction are incorporated or entrapped in a solid polymeric structure comprising pullulan. In certain embodiments, the chemical reaction or multi-step reaction serves as a sensor. Accordingly the present application is also directed to sensors for performing the methods of the application. In certain embodiments, at least one of the reagents is a biomolecule and the sensor is a biosensor. In certain other embodiments, the solid polymeric structure comprising pullulan and the reagents for performing a chemical reaction form a convenient device for performing a chemical reaction.

Abstract: A method of operating a traffic management system may comprise identifying a vehicle queue in a first lane of a road based on sensor data from one or more connected vehicles traveling along the road, determining driving instructions for a connected vehicle within a queue management region in a second lane, adjacent to the first lane, to create a gap in front of the connected vehicle for a vehicle in the vehicle queue to change lanes into the gap, and transmitting the driving instructions to the connected vehicle.

Abstract: The present application relates to a vehicle whose shell material is modified with at least one additional secondary phase that acts as a cork. In the presence of an energy source (preferably ultrasound), the corks embedded in the shell are either removed from the shell to create permanent pores or perturbed within the shell to create transient pores that can control transport in or out of the vehicle.

Abstract: A trifunctional molecule is provided, comprising (i) a target-specific ligand, (ii) a ligand that binds a protein associated with a TCR complex, and (iii) a T cell receptor signaling domain polypeptide. Variants of the molecule are provided, including variants that exhibit optimized surface expression, transduction efficiency, and effector functionality. Variations include, for example, different ligands that bind CD3 epsilon (e.g., OKT3, L2K, F6A, UCHT1 and humanized UCHT1), different signaling domains, and different linkers between domains.

Abstract: Provided herein is a biosensor for detecting a target analyte in a sample comprising a first and second photoelectrode each comprising conductive substrate and photoactive material, a first and second capture probe functionalized on the first and second photoelectrode, respectively, and optionally one or more reporter moieties comprising a detectable label, wherein the first and second capture probe each, independently, provides a distance between the detectable label and the photoactive material in the presence of the target analyte, wherein intensity of detection signal dictated by the distance is generated from the first and second photoelectrode by transfer of electrons between the detectable label and the photoactive material, wherein a higher, or higher increase than in absence of sample, in the intensity of the detection signal from the first as compared to the second photoelectrode in the presence of the sample, is indicative of the presence of the target analyte.

Abstract: A novel synthetic functionalized backbone polymer is provided which is a polyanionic side-chain functionalized back-bone polymer comprising a hydrophilic backbone polymer functionalized with an activated alkene or epoxy group. The functionalized backbone polymer may be combined with a free or protected thiol-containing compound to form a crosslinked hydrogel having bio-medical application, and may additionally be combined with a hydrogel matrix to yield a hydrogel system useful for in vivo delivery of cells and other therapeutic agents.

Abstract: The present application relates to methods of using compounds of Formulae (I) and (II): for treatment of various cancers. The application further relates to pharmaceutical compositions and uses comprising the compounds of the application.

Abstract: Optical transmitters and optical receivers utilizing long wave infrared light for use with an earth-orbiting satellite communication system, and a structure including an intracavity optical nonlinear process, are described herein. The transmitters include a pumping laser diode with a fast-axis collimating lens and a pumping wavelength ?0, operating in a continuous wavelength (CW) mode. The transmitters also include a laser cavity having a beam combiner or a dichroic mirror, a laser crystal with a lasing wavelength ?1 and a difference frequency generation orientation patterned semiconductor to generate long wave-IR light. The transmitters also include a second laser at a wavelength ?2, operating in a modulation mode. The receivers have a similar structure to the transmitters, utilizing a sum frequency generation orientation patterned semiconductor to convert long wave-IR light into the short wave-IR.

Abstract: The present application relates to compounds of Formula I comprising an antibody binding domain (ABD) comprising a hapten that binds to an antibody in a subject, the antibody comprising a hapten binding site, an antibody labelling domain (ALD) comprising a functional group that forms a covalent bond with an amino acid in the antibody that is proximal to the hapten binding site and the formation of the covalent bond results in elimination of the ABD and either a target binding domain (TBD) or a detection moiety domain (DMD), each domain being optionally connected with independently selected linkers. The present application also includes methods and uses of the compounds, for example, for immune recognition of target cells by recruited labelled antibodies.

Abstract: A difference frequency generation optical transmitter and sum frequency generation optical receiver operating in the mid-infrared wavelength range for use in free space optical satellite communications are described. By using mid-infrared light, the transmitter/receiver can mitigate atmospheric scintillation, scattering, and other non-ideal optical effects in the communication channel. This is achieved through the use of nonlinear optical crystals designed for difference frequency generation in the case of the transmitter and sum frequency generation for the receiver. High-speed modulated communication signals can thus be frequency converted to the mid-infrared wavelength range by a relatively low cost, compact and high-power optical communication system.

Abstract: Methods for post-fabrication trimming of a silicon ring resonator are disclosed. Methods include fabricating a heating element, positioned within 2 microns of the silicon ring resonator, subjecting the silicon ring resonator to energetic ion implantation, and annealing the silicon ring resonator, using the heating element. The energetic ion implantation shifts a resonance of the silicon ring resonator towards the red side of the electro-magnetic spectrum. The annealing shifts the resonance of the silicon ring resonator towards the blue side of the electro-magnetic spectrum.

Abstract: The present application describes process for preparing an ortho-allylated hydroxy aryl compounds such as compounds of Formula (I) by reacting an allylic alcohol with a hydroxy aryl compound in the presence of aluminum compound selected from alumina and aluminum alkoxides and in a non-protic solvent wherein at least one carbon atom ortho to the hydroxy group in the hydroxy aryl compound is unsubstituted. The present application also includes compounds of Formula (I).

Abstract: A method for determining the risk of acute kidney injury (AKI) in a mammal following cardiac surgery is provided. The method comprises determining the sample value of IL-6 or hFABP concentration, or the ratio of IL-6 to IL-10, in a biological sample from the mammal, either prior to cardiac surgery or within 6 hours following surgery; comparing the sample value to a corresponding reference value; and determining that the mammal is at risk of acute kidney injury following cardiac surgery if the sample value is greater than the corresponding reference value.